Poolbeg Pharma Ltd. (GB:POLB) has released an update.
Poolbeg Pharma Ltd has secured an exclusive option to acquire a new treatment for Behçet’s Disease from Silk Road Therapeutics, aiming to address the unmet medical need for this condition that currently lacks a cure. The treatment, a novel topical formulation of Pentoxifylline, has shown promise in a Phase 2 trial, outperforming the standard care by accelerating the healing of oral ulcers. With secured Fast Track and Orphan Drug Designations from the FDA, Poolbeg Pharma is now conducting due diligence to ascertain the clinical approval pathway for potential expedited U.S. approval.
For further insights into GB:POLB stock, check out TipRanks’ Stock Analysis page.
